Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.1% in the afternoon session after the company ...

Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective cut by analysts at Morgan Stanley from $39.00 to $32.00 in a research report issued on Wednesday,Benzinga reports. The brokerage ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report)’s stock price was down 5.2% during trading on Monday after Leerink Partners lowered their price target on the stock from $18.00 to $15.00. Leerink ...

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the ...

In the closing of the recent trading day, Moderna (MRNA) stood at $24.61, denoting a -4.91% move from the preceding trading day.

The company's equity performance has been challenging throughout the year. Even after Wednesday's substantial advance, the stock remains down 37% year-to-date. Moderna's most recent quarterly report ...

Moderna announces its new COVID-19 vaccine secured FDA clearance for seniors and at-risk individuals. Moderna's mNEXSPIKE shows a higher vaccine efficacy as well as a similar safety profile compared ...

Moderna has struggled since COVID-19 vaccine demand has shrunk. The stock has correspondingly declined, as revenue has nosedived over the last few years. The long game is clinical trials in oncology ...